Tech Company Financing Transactions
Protillion Biosciences Funding Round
Protillion Biosciences, based in Burlingame, secured $18 million from Arch Venture Partners and Illumina Ventures.
Transaction Overview
Company Name
Announced On
12/19/2022
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series A
Investors
Arch Venture Partners (Lead Investor)
Illumina Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to scale its hardware infrastructure and development teams.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1400 Marsten Rd. M
Burlingame, CA 94010
USA
Burlingame, CA 94010
USA
Phone
Undisclosed
Website
Email Address
Overview
Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Curtis Layton
Co-Founder
Will Greenleaf
Co-Founder
David Walt
Browse more venture capital transactions:
Prev: 12/19/2022: Arrakis Finance venture capital transaction
Next: 12/19/2022: Vizabli venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs